• All
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z

• B
• Bae, Sungyeun
  Seoul National University
• PI-026 - EFFECT OF CYP2D6 PHENOTYPE ON PHARMACOKINETICS OF DWN12088, A NOVEL PROLYL-TRNA SYNTHETASE INHIBITOR, IN A FIRST-IN HUMAN STUDY.
  Sungyeun Bae
  Favorite
• Balazki, Pavel
  esqLABS GmbH
• PII-094 - 4Β-OH CHOLESTEROL AS ENDOGENOUS BIOMARKER FOR CYP3A4 INDUCER DDI STUDIES – A PBPK PLATFORM FOR IN SILICO COMPOUND TESTING.

  
  Pavel Balazki
  Favorite
• PWI-002 - 4Β-OH CHOLESTEROL AS ENDOGENOUS BIOMARKER FOR CYP3A4 INDUCER DDI STUDIES – A PBPK PLATFORM FOR IN SILICO COMPOUND TESTING.

  
  Pavel Balazki
  Favorite
• Bank, Paul
  University of Amsterdam
• EP-015 - EXPLAINING INTERPATIENT VARIABILITY OF ADALIMUMAB RESPONSE IN CHRONIC PLAQUE PSORIASIS BY PHARMACOKINETIC-PHARMACODYNAMIC MODELLING: RESULTS FROM THE OPTIMAP STUDY.
  Paul Bank
  Favorite
• Berger, Benjamin
  Idorsia Pharmaceuticals Ltd
• PI-062 - EFFECT OF ACT-539313, A SELECTIVE OREXIN-1 RECEPTOR ANTAGONIST, ON THE CYTOCHROME P450 2C9, 2C19, AND 3A4 SUBSTRATES FLURBIPROFEN, OMEPRAZOLE, AND MIDAZOLAM USING A COCKTAIL APPROACH.
  Benjamin Berger
  Favorite
• PII-054 - EFFECT OF COMPLEMENT FACTOR 5A RECEPTOR 1 (C5AR1) ANTAGONIST ACT-1014-6470 ON THE CYTOCHROME P450 2C19 AND 3A4 SUBSTRATES OMEPRAZOLE AND MIDAZOLAM IN A COCKTAIL STUDY IN HEALTHY SUBJECTS.
  Benjamin Berger
  Favorite
• Bhagwat, Sharvari
  Inhibrx
• PII-092 - YOU MUST CHOOSE, BUT CHOOSE WISELY – PHASE 2 DOSE SELECTION FOR INBRX-109, A TETRAVALENT DEATH RECEPTOR 5 (DR5) AGONIST ANTIBODY.

  
  Sharvari Bhagwat
  Favorite
• Bhatnagar, Sumit
  Abbvie Inc.
• PII-004 - PHASE 1 DEVELOPMENT OF RAVAGALIMAB, AN ANTI CD40 MONOCLONAL ANTIBODY, TO SUPPORT DOSE SELECTION FOR PHASE 2.

  
  Sumit Bhatnagar
  Favorite
• Bird, Helen
  Johns Hopkins University
• PII-128 - HOW DOES CLEARANCE OF ILLICITLY MANUFACTURED FENTANYL AFFECT WITHDRAWAL DURING EARLY BUPRENORPHINE TREATMENT?

  
  Helen Bird
  Favorite
• Block, Michael
  Bayer AG
• PI-093 - A COMPREHENSIVE MIDD APPROACH TO ASSESS THE SAFETY AND EFFICACY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS FOR EARLY DECISION MAKING.
  Michael Block
  Favorite
• PII-123 - A MODEL-BASED META-ANALYSIS TO ASSESS THE SIMILARITIES AND DIFFERENCES OF CLINICAL SAFETY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS.
  Michael Block
  Favorite
• Boof, Marie-Laure
  Idorsia Pharmaceuticals Ltd
• PI-034 - A MULTI-PURPOSE FIRST-IN-HUMAN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-777991, AN ORAL C-X-C MOTIF CHEMOKINE RECEPTOR 3 (CXCR3) ANTAGONIST.
  Marie-Laure Boof
  Favorite
• Brees, Laurane
  Janssen Pharmaceuticals
• PII-012 - FROM RIFAMPIN TO CARBAMAZEPINE: HOW TO PROPERLY MANAGE SAFETY IN A CHANGING DRUG-DRUG-INTERACTION TRIAL LANDSCAPE.

  
  Laurane Brees
  Favorite
• Brooks, Jordan
  University of California, San Francisco
• PI-052 - CYCLOPHOSPHAMIDE POPULATION PHARMACOKINETICS IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION.

  
  Jordan Brooks
  Favorite
• Brown, Karen
  University of Montana
• PI-089 - NATIONAL MEETING ON COMMUNITY ENGAGED RESEARCH TOWARDS PRECISION MEDICINE WITH AMERICAN INDIAN AND ALASKA NATIVE PEOPLE.

  
  Karen Brown
  Favorite